Literature DB >> 33750830

A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy.

Li Tan1,2,3, Yi Tang1, Gaiqin Pei1,3, Zhengxia Zhong4,3, Jiaxing Tan1,3, Ling Zhou5,3, Dongmei Wen6,3, David Sheikh-Hamad2, Wei Qin7.   

Abstract

It was reported that histopathologic lesions are risk factors for the progression of IgA Nephropathy (IgAN). The aim of this study was to investigate the relationships between mesangial deposition of C1q and renal outcomes in IgAN. 1071 patients with primary IgAN diagnosed by renal biopsy were enrolled in multiple study centers form January 2013 to January 2017. Patients were divided into two groups: C1q-positive and C1q-negative. Using a 1: 4 propensity score matching (PSM) method identifying age, gender, and treatment modality to minimize confounding factors, 580 matched (out of 926) C1q-negative patients were compared with 145 C1q-positive patients to evaluate severity of baseline clinicopathological features and renal outcome. Kaplan-Meier and Cox proportional hazards analyses were performed to determine whether mesangial C1q deposition is associated with renal outcomes in IgAN. During the follow-up period (41.89 ± 22.85 months), 54 (9.31%) patients in the C1q negative group and 23 (15.86%) patients in C1q positive group reached the endpoint (50% decline of eGFR and/or ESRD or death) respectively (p = 0.01) in the matched cohort. Significantly more patients in C1q negative group achieved complete or partial remission during the follow up period (P = 0.003) both before and after PSM. Three, 5 and 7-year renal survival rates in C1q-positive patients were significantly lower than C1q-negative patients in either unmatched cohort or matched cohort (all p < 0.05). Furthermore, multivariate Cox regression analysis showed that independent risk factors influencing renal survival included Scr, urinary protein, T1-T2 lesion and C1q deposition. Mesangial C1q deposition is a predictor of poor renal survival in IgA nephropathy.Trial registration TCTR, TCTR20140515001. Registered May 15, 2014, http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=1074 .

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33750830      PMCID: PMC7943768          DOI: 10.1038/s41598-021-84715-7

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  24 in total

1.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

2.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.

Authors:  Andrew S Levey; Lesley A Stevens
Journal:  Am J Kidney Dis       Date:  2010-04       Impact factor: 8.860

Review 3.  Complement and the kidney: what the nephrologist needs to know in 2006?

Authors:  Stefan P Berger; Anja Roos; Mohamed R Daha
Journal:  Nephrol Dial Transplant       Date:  2005-10-04       Impact factor: 5.992

Review 4.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

5.  Absence of mesangial C1q deposition is associated with resolution of proteinuria and hematuria after tonsillectomy plus steroid pulse therapy for immunoglobulin a nephropathy.

Authors:  Hiroki Nishiwaki; Takeshi Hasegawa; Yoshikuni Nagayama; Nobuharu Kaneshima; Mamiko Takayasu; Makoto Hirose; Daisuke Komukai; Yoshihiko Inoue; Fumihiko Koiwa; Ashio Yoshimura
Journal:  Nephron       Date:  2015-04-21       Impact factor: 2.847

Review 6.  Diagnosis and classification of IgA nephropathy.

Authors:  Hsin-Hui Yu; Bor-Luen Chiang
Journal:  Autoimmun Rev       Date:  2014-01-13       Impact factor: 9.754

Review 7.  Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.

Authors:  Hernán Trimarchi; Jonathan Barratt; Daniel C Cattran; H Terence Cook; Rosanna Coppo; Mark Haas; Zhi-Hong Liu; Ian S D Roberts; Yukio Yuzawa; Hong Zhang; John Feehally
Journal:  Kidney Int       Date:  2017-03-22       Impact factor: 10.612

Review 8.  The pathogenesis of IgA nephropathy.

Authors:  Richard J Glassock
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-03       Impact factor: 2.894

9.  Association of C1q deposition with renal outcomes in IgA nephropathy.

Authors:  Hong-Joo Lee; So Young Choi; Kyung Hwan Jeong; Ji-Youn Sung; Sung Kyoung Moon; Ju-Young Moon; Sang-Ho Lee; Tae-Won Lee; Chun-Gyoo Ihm
Journal:  Clin Nephrol       Date:  2013-08       Impact factor: 0.975

10.  The immunohistology of IgA nephropathy.

Authors:  J C Jennette
Journal:  Am J Kidney Dis       Date:  1988-11       Impact factor: 8.860

View more
  1 in total

Review 1.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.